Literature DB >> 23251764

Eplerenone: is it time to add this drug to current heart failure therapy?

Bertram Pitt, Faiez Zannad.   

Abstract

Entities:  

Year:  2012        PMID： 23251764      PMCID： PMC3513899          DOI： 10.1177/2040622311429891

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN： 2040-6223            Impact factor:   5.091


× No keyword cloud information.
  10 in total

1.  Eplerenone in patients with systolic heart failure and mild symptoms.

Authors:  Faiez Zannad; John J V McMurray; Henry Krum; Dirk J van Veldhuisen; Karl Swedberg; Harry Shi; John Vincent; Stuart J Pocock; Bertram Pitt
Journal:  N Engl J Med       Date:  2010-11-14       Impact factor: 91.245

2.  Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.

Authors:  Masayuki Yamaji; Takayoshi Tsutamoto; Chiho Kawahara; Keizo Nishiyama; Takashi Yamamoto; Masanori Fujii; Minoru Horie
Journal:  Am Heart J       Date:  2010-11       Impact factor: 4.749

3.  2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation.

Authors:  Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2009-04-14       Impact factor: 24.094

Review 4.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur J Heart Fail       Date:  2008-09-16       Impact factor: 15.534

5.  Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure.

Authors:  C A Farquharson; A D Struthers
Journal:  Circulation       Date:  2000-02-15       Impact factor: 29.690

6.  Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure.

Authors:  Bertram Pitt; Harvey White; Jose Nicolau; Felipe Martinez; Mihai Gheorghiade; Michael Aschermann; Dirk J van Veldhuisen; Faiez Zannad; Henry Krum; Robin Mukherjee; John Vincent
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

7.  Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.

Authors:  Bertram Pitt; Willem Remme; Faiez Zannad; James Neaton; Felipe Martinez; Barbara Roniker; Richard Bittman; Steve Hurley; Jay Kleiman; Marjorie Gatlin
Journal:  N Engl J Med       Date:  2003-03-31       Impact factor: 91.245

8.  The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators.

Authors:  B Pitt; F Zannad; W J Remme; R Cody; A Castaigne; A Perez; J Palensky; J Wittes
Journal:  N Engl J Med       Date:  1999-09-02       Impact factor: 91.245

9.  Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes.

Authors:  J I Davies; M Band; A Morris; A D Struthers
Journal:  Diabetologia       Date:  2004-09-09       Impact factor: 10.122

Review 10.  Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.

Authors:  Justin A Ezekowitz; Finlay A McAlister
Journal:  Eur Heart J       Date:  2008-12-09       Impact factor: 29.983
  10 in total
  2 in total

Review 1.  Eplerenone: a review of its use in patients with chronic systolic heart failure and mild symptoms.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

2.  The role of renin-angiotensin system in patients with left ventricular assist devices.

Authors:  Alexandros Briasoulis; Ernesto Ruiz Duque; Dimitrios Mouselimis; Anastasios Tsarouchas; Constantinos Bakogiannis; Paulino Alvarez
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2020 Oct-Dec       Impact factor: 1.636
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.